Dual Immunotherapy Makes Strides against HCC
Unknown authors
Abstract
In the phase III HIMALAYA trial, a single priming dose of tremelimumab plus once-monthly durvalumab was associated with better overall survival compared with sorafenib as first-line treatment for patients with inoperable hepatocellular carcinoma.
Topics & Concepts
DurvalumabTremelimumabSorafenibHepatocellular carcinomaMedicineImmunotherapyHepatocellular cancerOncologyCancer researchInternal medicineDual (grammatical number)Cancer immunotherapyImmune systemPriming (agriculture)NivolumabImmunologyCancerBlockadeImmune checkpointHepatocellular Carcinoma Treatment and PrognosisLiver physiology and pathologyCancer Immunotherapy and Biomarkers